San Francisco, CA – [Insert Date] – Kyverna Therapeutics is poised to make a significant impact on the treatment landscape for Stiff-Person Syndrome (SPS), a rare and debilitating autoimmune neurological disorder. The company has announced compelling one-year data from its pivotal Phase III KYSA-8 study, demonstrating sustained and clinically meaningful improvements in patients treated with its investigational CAR-T therapy, miv-cel (mivocabtagene autoleucel). This breakthrough offers a beacon of hope for individuals living with SPS, a condition for which no FDA-approved treatments currently exist.
The promising results from the KYSA-8 study, which met its primary and secondary endpoints at the 16-week mark and have now been extended to a full year, are poised to be a cornerstone of Kyverna’s upcoming Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). This strategic move positions Kyverna to potentially secure a first-to-market advantage in a therapeutic area desperately in need of innovation.
The Unmet Need in Stiff-Person Syndrome
Stiff-Person Syndrome (SPS) is a chronic, progressive, and profoundly disabling autoimmune neurological disorder characterized by severe muscle stiffness, rigidity, and agonizing spasms. These symptoms can affect the trunk, abdomen, and limbs, severely impacting mobility, quality of life, and independence. The exact prevalence of SPS is not well-defined due to diagnostic challenges, but it is considered an ultra-rare disease. Public awareness of SPS has been amplified in recent years, notably by the courageous public disclosure of her diagnosis by global superstar Céline Dion in 2022, bringing the profound challenges faced by SPS patients into sharper focus.
Currently, the therapeutic armamentarium for SPS is severely limited. While some treatments aim to manage symptoms, such as muscle relaxants and immunosuppressants, none are specifically approved by the FDA for SPS. The pipeline for novel SPS therapies is also notably sparse, underscoring the critical need for groundbreaking treatments that can address the underlying autoimmune pathology of the disease. This void in approved therapies creates a significant opportunity for Kyverna Therapeutics to introduce a transformative treatment option.
A Glimpse into the KYSA-8 Study: Sustained Efficacy and Safety
The KYSA-8 study (NCT06588491) is a registrational trial evaluating the efficacy and safety of miv-cel in adults with SPS. The study’s design focuses on assessing the impact of miv-cel on key functional measures and disease-specific symptoms. The most recent data, presented at the American Academy of Neurology (AAN) Annual Meeting in April 2026, have provided compelling evidence of the therapy’s sustained benefit.
Key Efficacy Findings at 12 Months:
- Significant Improvement in Mobility: Patients treated with miv-cel demonstrated a sustained 49% improvement in the timed 25-Foot Walk (T25FW) at month 12. This represents a remarkable continuation of the 46% improvement observed at the initial 16-week assessment, highlighting the durability of miv-cel’s effect.
- Near-Healthy Mobility Achieved: Crucially, more than one-third of patients in the study were able to complete the T25FW in less than 5 seconds. This performance is comparable to the typical walking times of healthy adults, indicating a profound restoration of mobility for a significant portion of the treated population.
- Durability of Clinically Meaningful Improvement: Of the patients who achieved a clinically meaningful improvement in their T25FW at the primary analysis, an impressive 95% maintained this benefit at the 12-month mark. This high rate of sustained benefit is a critical factor for regulatory approval and patient well-being, suggesting that a single administration of miv-cel may offer long-lasting relief.
Safety Profile:
The safety data from the KYSA-8 study further bolster the potential of miv-cel. The anti-CD19 CAR-T therapy, which is designed to stimulate CD28, was found to be well-tolerated. Importantly, there were no instances of high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), which are known potential risks associated with CAR-T therapies. Furthermore, no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) were reported. This favorable safety profile is paramount for a therapy targeting a chronic and potentially life-threatening condition like SPS.
Official Responses and Expert Endorsements
The positive outcomes of the KYSA-8 trial have garnered significant attention from the medical and scientific communities. Dr. Amanda Piquet, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine, Céline Dion Foundation endowed chair, and lead investigator of the KYSA-8 trial, expressed strong enthusiasm for the findings.
"The results from KYSA-8 are compelling, particularly given the severe burden of SPS and the absence of approved therapies," stated Dr. Piquet. "After a single dose of miv-cel, the sustained improvements observed in mobility, stiffness, and other disease-specific measures, together with a well-tolerated profile, underscore its potential to deliver significant, long-lasting benefit to patients with SPS."
Her endorsement highlights the transformative potential of miv-cel, emphasizing not only the functional improvements but also the therapy’s favorable safety and tolerability, which are critical considerations for patient care.
Kyverna Therapeutics’ leadership has also conveyed their optimism and strategic outlook. The inclusion of the one-year data in their rolling BLA submission to the FDA signifies their confidence in miv-cel’s potential to meet regulatory requirements and ultimately become the first approved treatment for SPS. This proactive approach underscores their commitment to accelerating access for patients who have long awaited effective therapeutic options.
Broader Implications and Future Directions
The success of miv-cel in SPS has significant implications beyond this specific indication. It validates the therapeutic potential of CAR-T cell therapy for a range of autoimmune disorders, a field that is rapidly expanding. The ability of miv-cel to selectively target and eliminate B cells responsible for producing autoantibodies, which are believed to play a central role in SPS pathogenesis, opens doors for similar approaches in other autoimmune conditions.
A Look at the Competitive Landscape:
While Kyverna appears to be at the forefront of SPS treatment development with miv-cel, other entities are also exploring therapeutic avenues. Kedrion, for instance, recently received FDA orphan drug designation for its product Qivigy (immune globulin Intravenous human 10% solution), which is currently in a Phase III clinical study for SPS (NCT07552987). While this represents progress in the broader SPS landscape, miv-cel’s CAR-T mechanism of action offers a distinct, potentially disease-modifying approach, differentiating it from conventional immunotherapies.
Promising Data in Generalised Myasthenia Gravis (gMG):
Adding to Kyverna’s positive momentum, the company has also reported encouraging longer-term data from its Phase II/III KYSA-6 study (NCT06193889) of miv-cel in generalized Myasthenia Gravis (gMG). Analysis of up to 18 months of treatment in the Phase II portion revealed that all seven patients achieved clinically meaningful improvements in both the Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at 24 weeks. These improvements were sustained at the one-year mark for those who have been on treatment for that duration.
The MG-ADL and QMG are the co-primary endpoints for the ongoing Phase III portion of the KYSA-6 study. The positive results in gMG further solidify the potential of miv-cel as a broad-spectrum CAR-T therapy for autoimmune diseases. The market for gMG is substantial, with GlobalData projecting it to reach $13 billion by 2034, highlighting the significant commercial and therapeutic impact miv-cel could have in this area as well.
Conclusion: A New Era for Autoimmune Disease Treatment
Kyverna Therapeutics’ sustained success in the KYSA-8 trial for Stiff-Person Syndrome marks a pivotal moment in the quest for effective treatments for rare autoimmune neurological disorders. The robust one-year efficacy and favorable safety profile of miv-cel position it as a strong candidate for FDA approval, potentially ushering in a new era of CAR-T therapy for conditions with high unmet medical needs. As Kyverna progresses with its BLA submission, the patient community and the broader medical field will be watching closely, anticipating the arrival of a therapy that could fundamentally change the lives of those living with the debilitating effects of SPS. The promising data from the gMG study further underscores Kyverna’s commitment to leveraging advanced cellular therapies to address a spectrum of challenging autoimmune diseases.
About the Author
